Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytoskeleton-associated protein 2-like (CKAP2L) is a microtubule-associated protein essential for organizing the mitotic spindle and promoting proper cell-cycle progression in neural progenitor cells[1][2][3][4][6]. CKAP2L (also called Radmis) localizes to mitotic spindles and radial fibers during cell division, ensuring microtubule stability and accurate chromosome segregation[4][6]. Loss-of-function mutations in CKAP2L cause Filippi syndrome, a rare congenital disorder involving microcephaly, syndactyly, growth retardation, and intellectual disability, by disrupting neural stem/progenitor cell mitosis[1][2][3][4][6]. CKAP2L is also implicated in tumorigenesis, with overexpression linked to cell proliferation and progression in several cancer types[4]. This protein is not currently an established therapeutic target, and there are no drugs or chemical inhibitors specifically known to target CKAP2L.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytoskeleton-associated protein 2-like (CKAP2L).